Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan Pharma's gross profit for the
three
months ended in Mar. 2026 was €5.10 Mil. InnoCan Pharma's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €19.52 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. InnoCan Pharma's gross profit for the
three
months ended in Mar. 2026 was €5.10 Mil. InnoCan Pharma's Revenue for the
three
months ended in Mar. 2026 was €5.59 Mil. Therefore, InnoCan Pharma's Gross Margin % for the quarter that ended in Mar. 2026 was 91.11%.
InnoCan Pharma had a gross margin of 91.11% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 8 years, the highestGross Margin % of InnoCan Pharma was 89.93%. The lowest was 40.00%. And the median was 85.03%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
InnoCan Pharma had a gross margin of 91.11% for the quarter that ended in Mar. 2026 => Durable competitive advantage
InnoCan Pharma Gross Profit Related Terms
InnoCan Pharma Gross Profit Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Gross Profit vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.52 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
InnoCan Pharma (FRA:IP40) has a Gross Profit of €19.52 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Gross Profit too high?
InnoCan Pharma's current Gross Profit is €19.52 Mil. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Gross Profit compare to PG and CL?
InnoCan Pharma's Gross Profit of €19.52 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Consumer Packaged Goods company?
A good Gross Profit depends on the Consumer Packaged Goods industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Gross Profit is €19.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.50, compared to a current price of €1.51 — trading 84.2% below its estimated fair value. The current Gross Profit is €19.52 Mil. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Gross Profit is €19.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.51 is trading 84.2% below its estimated GF Value™ of €9.50.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Gross Profit: €19.52 Mil
GF Value™: €9.50 vs. price of €1.51 (84.2% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for FRA:IP40
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
